FDA Approves Datopotamab Deruxtecan for EGFR-Mutated NSCLC
June 23rd 2025The FDA approved datopotamab deruxtecan-dlnk (Datroway; Daiichi Sankyo) for the treatment of locally advanced or metastatic EGFR-mutated non–small cell lung cancer (NSCLC) after receipt of EGFR-directed therapy and platinum-based chemotherapy.
DVRd Improves MRD Negativity, Maintains Quality of Life in Multiple Myeloma
June 12th 2025Two posters presented at the 2025 European Hematology Association Congress support combination therapy with daratumumab, bortezomib, lenalidomide, and dexamethasone (DVRd) in transplant-ineligible or deferred newly diagnosed multiple myeloma.
AMCP Applauds ECAPS Act of 2025: Adam Colborn, JD
June 4th 2025Adam Colborn, JD, associate vice president for congressional affairs, Academy of Managed Care Pharmacy (AMCP), shares updates on the Ensuring Community Access to Pharmacist Services (ECAPS) Act of 2025, which was introduced in the House of Representatives last month.